--- canonical_name: Navitoclax alternate_names: ABT-263, ABT263 canonical_topic: Navitoclax as a Senolytic Therapy short_topic_lc: navitoclax_senolytic creation_date: 2026-0922-0928 creator_ai_fullname: Opus 5 ep_keywords: Bcl-2 Inhibitors, BH3 Mimetics, Senolytics --- # Navitoclax as a Senolytic Therapy
Evidence Review created on 09/22/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5 **Also known as:** ABT-263, ABT263 ## Motivation Navitoclax is an oral compound first built to treat blood cancers by blocking a family of proteins that keep damaged cells alive. Later laboratory work showed that the same blockade also kills senescent cells — cells that have permanently stopped dividing yet refuse to die, and that instead leak inflammatory signals into surrounding tissue. Because such cells build up in almost every organ with age, a compound that removes them attracts interest far beyond cancer medicine. Navitoclax was given to people with blood and lung cancers for more than a decade, and a fall in platelet counts set the ceiling on how much could be administered. In parallel, work in mice reported that removing senescent cells restored the function of worn-out blood-forming and muscle stem cells. That result turned navitoclax from a cancer drug into a reference tool in longevity research, though no human study has yet measured whether it clears senescent cells in people. This review examines navitoclax used as a senolytic — an agent intended to destroy senescent cells. It sets out the proposed mechanism, the human and animal evidence, the documented harms, the dosing schedules that have been used, and the places where the evidence remains absent. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading High-level material that explains navitoclax, or the senolytic drug class it belongs to, in substantial depth. * [Precision Targeting of Senescent Cells](https://lifespan.io/precision-targeting-of-senescent-cells/) - Josh Conway Reports a sugar-coated micelle carrier that releases navitoclax only inside senescent cells, the leading strategy for separating its senolytic action from its platelet toxicity. * [Senolytic drugs: from discovery to translation](https://pubmed.ncbi.nlm.nih.gov/32686219/) - Kirkland & Tchkonia, 2020 Narrative review by the group that first classified navitoclax as a senolytic; explains the hit-and-run dosing logic and catalogues the preclinical conditions the class has altered. * [#112 - Ned David, Ph.D.: How cellular senescence influences aging, and what we can do about it](https://peterattiamd.com/neddavid/) - Peter Attia Long-form interview with the co-founder of a senolytics company on why removing senescent cells is expected to affect several age-related diseases at once, and on the translation obstacles. * [Judith Campisi, Ph.D., on Cellular Senescence, Mitochondrial Dysfunction, Cancer & Aging](https://www.foundmyfitness.com/episodes/judy-campisi) - Rhonda Patrick Interview with the researcher who defined the senescence-associated secretory phenotype (the inflammatory output of senescent cells), which makes them a target for navitoclax and other senolytics. * [Senolytics for Longer Life](https://www.lifeextension.com/magazine/2021/2/senolytics) - Life Extension Magazine Clinician interview describing how senolytics are actually scheduled in practice — intermittent short courses rather than daily use — the same dosing logic navitoclax follows. Content from two priority experts is absent. Web and on-site searching of hubermanlab.com and chriskresser.com returned no episode, article or transcript that discusses navitoclax or the senolytic drug class in substantial depth; only passing mentions inside broader episodes were found, which do not meet the depth bar applied here. ## Grokipedia * [Navitoclax](https://grokipedia.com/page/Navitoclax) A dedicated article covering navitoclax as an investigational oral inhibitor of the proteins that keep cells from self-destructing, with its oncology trial history and platelet toxicity. ## Examine No Examine article exists for navitoclax. Examine.com does not typically cover prescription and investigational medications, restricting its coverage to dietary supplements and nutrition topics. ## ConsumerLab No ConsumerLab article exists for navitoclax. ConsumerLab does not typically cover prescription or investigational medications, as its testing programme is limited to commercially sold supplements and foods. ## Systematic Reviews Systematic reviews and meta-analyses bearing on navitoclax and the BCL-2 family (B-cell lymphoma 2, a group of proteins that block a cell's self-destruct programme), covering both its measured benefits and its principal harm. * [Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia](https://pubmed.ncbi.nlm.nih.gov/25053389/) - Kaefer et al., 2014 Pools trial data to model the dose-dependent platelet fall, the harm that caps navitoclax exposure. Funded by the manufacturer, AbbVie. * [Evaluation of Drugs with Selective Inhibitors Targeting the Anti-Apoptotic Protein B-cell Lymphoma 2 (BCL-2) with Pro-Apoptotic and Antineoplastic Activities in Grade IV Glioblastoma](https://pubmed.ncbi.nlm.nih.gov/41784189/) - Baloglu et al., 2026 Systematically compares navitoclax with related inhibitors, concluding its combination activity is real but constrained by dose-related platelet loss. * [Role of Bcl-2 family anti-apoptosis inhibition in overcoming therapeutic resistance in prostate cancer: A systematic review](https://pubmed.ncbi.nlm.nih.gov/40818830/) - Jaya et al., 2025 Pools twelve preclinical studies of BCL-2 family inhibitors including navitoclax, finding they both amplify standard therapy and clear therapy-induced senescent cells. * [Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/41761659/) - Tan et al., 2026 Pools thirteen combination regimens, including navitoclax, in myelofibrosis (a bone-marrow scarring blood cancer), quantifying spleen response and severe blood-count toxicity. No systematic review or meta-analysis evaluates navitoclax as a senolytic for any ageing-related outcome; the pooled literature covers only its oncology use and its haematological toxicity. ## Mechanism of Action Senescent cells survive despite constant internal stress because they raise their levels of anti-apoptotic proteins — proteins that block a cell's built-in self-destruct programme, apoptosis. Navitoclax is a BH3 mimetic (a small molecule shaped like the natural trigger domain of pro-death proteins). It binds BCL-2, BCL-xL (B-cell lymphoma extra large) and BCL-w (B-cell lymphoma w) with very high affinity, but binds MCL-1 (myeloid cell leukaemia 1) only weakly. Occupying those three sites releases the executioner proteins BAX and BAK, which puncture the mitochondrial membrane and kill the cell. Because senescent cells are held alive chiefly by BCL-xL and BCL-w, navitoclax kills them at concentrations that spare most healthy cells. Selectivity is partial and cell-type dependent: it eliminates senescent endothelial cells and lung fibroblasts but not senescent preadipocytes, which depend on different survival proteins ([Zhu et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26711051/)). A competing mechanistic reading holds that much of its observed benefit reflects broad cytotoxicity to any BCL-xL-dependent cell rather than true senescence selectivity — platelets, which depend entirely on BCL-xL, die at the same doses ([Mason et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17382885/)). Pharmacologically, navitoclax is orally absorbed, more than 99% plasma-protein bound, widely distributed to tissue but with negligible central nervous system penetration, and has a terminal half-life of roughly 15–25 hours. It is metabolised in vitro by CYP3A4 (an enzyme in the liver that breaks down many medications), although CYP3A inhibition does not raise exposure meaningfully in patients ([Salem et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24692738/)). ## Historical Context & Evolution Navitoclax was designed at Abbott Laboratories as an orally available successor to ABT-737, with the explicit aim of killing cancer cells that overproduce BCL-2. Its original intended use was oncology alone: relapsed lymphoid malignancy, chronic lymphocytic leukaemia (a slow-growing cancer of white blood cells) and small-cell lung cancer. The first dose-escalation study in lymphoid cancers established both a signal of activity and the constraint that has defined the compound ever since — a rapid, dose-proportional fall in platelets ([Wilson et al., 2010](https://pubmed.ncbi.nlm.nih.gov/21094089/)). Single-agent activity proved modest in solid tumours, and the programme was re-oriented toward combinations. The turn toward health optimisation came in 2015–2016, when two groups independently found that the same drug selectively killed senescent cells. One screen identified it as a potent senolytic that depleted senescent blood-forming and muscle stem cells in irradiated and naturally aged mice ([Chang et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26657143/)); a second showed that senescent cells specifically raise BCL-w and BCL-xL, and that inhibiting both is sufficient to remove them ([Yosef et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27048913/)). Scientific opinion has not settled. The early framing — navitoclax as the archetypal senolytic — has been tempered by reports of harm in aged tissue and by the redirection of effort toward safer BCL-xL-sparing designs, yet navitoclax remains the benchmark against which newer senolytics are measured, and the case against it rests largely on short-duration rodent work. ## Expected Benefits ### High 🟩 🟩 🟩 #### Reduction of Tumour Burden in BCL-2-Dependent Blood Cancers ⭕️ Not Central to Senolytic Therapy Adding navitoclax to ruxolitinib (a Janus kinase inhibitor, the standard oral drug for myelofibrosis) shrinks the enlarged spleen that defines advanced myelofibrosis, replicated in a randomised phase 3 trial ([Pemmaraju et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42378247/)) and an earlier phase 2 trial ([Harrison et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35180010/)). Single-agent navitoclax also produced partial responses in relapsed chronic lymphocytic leukaemia ([Roberts et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22184378/)). This bears on cancer control, not on senescent-cell burden. Both myelofibrosis trials were designed and funded by the manufacturer, AbbVie. **Magnitude:** In phase 3, 63.2% of patients on navitoclax plus ruxolitinib achieved a 35% or greater spleen volume reduction at week 24 versus 31.5% on ruxolitinib alone; 35% of chronic lymphocytic leukaemia patients treated at 110 mg daily or above reached a partial response. ### Medium 🟩 🟩 #### Regression of Bone Marrow Fibrosis ⭕️ Not Central to Senolytic Therapy In the phase 2 trial, adding navitoclax to ruxolitinib reduced the grade of scarring in the bone marrow, an effect ruxolitinib alone rarely produces and one interpreted as disease modification rather than symptom control ([Harrison et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35180010/)). Fibrosis regression is mechanistically adjacent to the anti-fibrotic effects claimed for senolytics, but here it is attributed to suppression of the malignant clone. Evidence rests on a single open-label, manufacturer-funded trial with no control arm, which is why it does not reach the higher grade. **Magnitude:** Bone marrow fibrosis improved by one to two grades in 33% (11 of 33) of evaluable patients, and anaemia response was achieved in 64% (7 of 11) of evaluable patients. ### Low 🟩 ### Speculative 🟨 #### Clearance of Senescent Cells and Rejuvenation of Aged Tissue Stem Cells Oral navitoclax depleted senescent blood-forming and muscle stem cells in aged mice, restoring their repopulating capacity ([Chang et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26657143/)). No human study has measured senescent-cell burden; the basis is animal work only. #### Preservation of Cardiac Function and Survival After Myocardial Infarction In aged mice, navitoclax removed senescent heart muscle cells, improved heart remodelling and filling, and raised survival after heart attack ([Walaszczyk et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30920115/)). The basis is a single rodent model. #### Reduction of Abnormal Brain Protein Build-Up In mice with tangle-forming brain disease, navitoclax suppressed senescence markers and reduced the abnormal protein build-up that seeds neuron-killing tangles ([Bussian et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30232451/)); neuron loss was prevented only by genetic clearance. Rodent work only. #### Improved Glucose Tolerance and Beta-Cell Function ⚠️ Conflicted Oral navitoclax improved glucose handling in mice ([Aguayo-Mazzucato et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31155496/)), but in obese mice the gain proved transient ([Sierra-Ramirez et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32584785/)). Net reading: the metabolic effect is real but not durable. #### Clearance of Therapy-Induced Senescent Cells After Chemotherapy Chemotherapy drives surviving tumour cells into senescence; navitoclax clears them in culture, though the mouse tumour-regrowth result was obtained with its galactose-tagged prodrug ([González-Gualda et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32233024/)). The basis is cell and rodent work only. #### Protection of Joint Cartilage in Osteoarthritis Intra-articular (into the joint) navitoclax cleared senescent cartilage cells and limited joint and underlying bone damage in a rat osteoarthritis model ([Yang et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32611834/)). The basis is rodent and cell-culture work only. #### Reversal of Established Lung Fibrosis In two mouse models of progressive fibrosing lung disease, navitoclax killed the apoptosis-resistant fibroblasts that drive scarring and reversed established fibrosis ([Cooley et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36752201/)). The basis is rodent and human-tissue work only. ## Benefit-Modifying Factors * **CYP3A4 and CYP3A5 variants:** No pharmacogenetic marker predicts navitoclax benefit. Strong CYP3A inhibition barely raises exposure ([Salem et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24692738/)), so variants in CYP3A4 or CYP3A5 (a related liver enzyme that also breaks down medications) are unlikely to shift the exposure driving response. * **BCL-2 family expression profile:** Response tracks which survival protein a cell depends on. High MCL-1, which navitoclax barely binds, predicts resistance; a high ratio of the pro-death protein BIM to MCL-1 or BCL-2 predicted response in leukaemia ([Roberts et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22184378/)). * **Baseline platelet count:** Platelet count sets the achievable dose. Trial protocols start patients above 150 × 10⁹/L at 200 mg daily but halve the starting dose at or below that threshold, so a low baseline mechanically limits exposure and therefore benefit. * **Senescent cell type present:** Navitoclax kills senescent endothelial cells and lung fibroblasts but not senescent preadipocytes ([Zhu et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26711051/)). Benefit is therefore tissue-specific, and fat-tissue senescence is largely outside its reach. * **Sex:** No sex difference in efficacy has been reported. The mouse bone study that found harm used both sexes and saw the effect in each ([Sharma et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32509782/)), and the myelofibrosis trials did not report sex-stratified response, so any difference remains unmeasured. * **Pre-existing marrow reserve and prior cytotoxic therapy:** Prior chemotherapy or an already fibrotic marrow lowers tolerated exposure. In myelofibrosis trials, dose escalation depended on platelet recovery, so patients with poor reserve rarely reached the target dose. * **Age and tissue senescent burden:** Older tissue carries more senescent cells, so the theoretical yield is larger; but the only in-vivo bone data come from 24-month-old mice, where navitoclax harmed rather than helped skeletal tissue ([Sharma et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32509782/)). ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 #### Thrombocytopenia A low platelet count (thrombocytopenia) is the defining and dose-limiting harm. It is on-target rather than idiosyncratic: platelets depend entirely on BCL-xL for survival, so inhibiting it shortens their lifespan directly ([Mason et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17382885/)). The fall is rapid, dose-proportional and reversible on interruption, and it has appeared in every trial across fifteen years, including the manufacturer-funded phase 3 study ([Pemmaraju et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42378247/)) and the phase 2 lung cancer study ([Rudin et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22496272/)). **Magnitude:** Grade 3 or 4 thrombocytopenia occurred in 54.0% of patients on navitoclax plus ruxolitinib versus 19.2% on ruxolitinib alone in phase 3, and in 41% of patients on single-agent navitoclax at 325 mg daily. #### Neutropenia A low neutrophil count (neutropenia — depletion of the white cells that fight bacteria) follows navitoclax at therapeutic doses and raises infection risk. It was documented in the first dose-escalation study ([Wilson et al., 2010](https://pubmed.ncbi.nlm.nih.gov/21094089/)) and again, far more frequently than with comparator alone, in the manufacturer-funded phase 3 trial ([Pemmaraju et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42378247/)). Unlike thrombocytopenia it is not a direct BCL-xL effect on mature cells but arises from progenitor loss, and it is generally reversible with dose reduction. **Magnitude:** Grade 3 or 4 neutropenia occurred in 40.3% on navitoclax plus ruxolitinib versus 8.8% on ruxolitinib alone; grade 3 or 4 neutropenia affected 18 of 55 patients in the first-in-human study. #### Gastrointestinal Toxicity Diarrhoea, nausea and vomiting are the most common non-haematological adverse events and are reported consistently across solid-tumour, lymphoid and myelofibrosis programmes ([Gandhi et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21282543/); [Roberts et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25942994/); [Pemmaraju et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42378247/)). Most events are grade 1 or 2 and manageable, but they drive discontinuation in a minority and worsen when navitoclax is combined with agents that themselves cause nausea. **Magnitude:** Any-grade diarrhoea affected 41.9% on navitoclax plus ruxolitinib versus 16.8% on ruxolitinib alone; in the solid-tumour phase 1 study, diarrhoea affected 40%, vomiting 36% and nausea 34%. #### Lymphopenia and Impaired Antibody Defence Navitoclax depletes B and T lymphocytes, because BCL-2 sustains lymphocyte survival. The first-in-human study recorded severe lymphopenia (a shortage of the white cells that mount specific immune responses) alongside frequent infection ([Wilson et al., 2010](https://pubmed.ncbi.nlm.nih.gov/21094089/)), and the rituximab combination study documented sustained loss of B cells and falling immunoglobulin M through the first year ([Roberts et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25942994/)). Recovery after stopping is slow relative to platelets. **Magnitude:** Grade 3 or 4 lymphopenia affected 18 of 55 patients, and grade 1 or 2 infection 39 of 55, in the first-in-human study; in the combination study, T cells fell by roughly 20% and immunoglobulin M by roughly 33%. #### Fatigue Fatigue is among the most frequently reported non-haematological adverse events and appears in every navitoclax programme, from the first-in-human lymphoid study ([Wilson et al., 2010](https://pubmed.ncbi.nlm.nih.gov/21094089/)) to the solid-tumour phase 1 ([Gandhi et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21282543/)). Its mechanism is not established; anaemia and the underlying malignancy both contribute, so it is only partly attributable to the drug. Events are predominantly grade 1 or 2 and reverse on interruption, but the frequency matters for any schedule intended to be repeated. **Magnitude:** Fatigue affected 21 of 55 patients in the first-in-human study and 34% of patients in the solid-tumour phase 1 study, almost all at grade 1 or 2. ### Medium 🟥 🟥 #### Anaemia Anaemia was the most frequent toxic effect in the first-in-human study, affecting 41 of 55 patients, almost all at grade 1 or 2 ([Wilson et al., 2010](https://pubmed.ncbi.nlm.nih.gov/21094089/)). The mechanism is marrow progenitor suppression rather than a direct BCL-xL effect on circulating red cells. In the myelofibrosis programme anaemia is confounded by the disease itself, which is why the grade rests on the single uncontrolled dose-escalation trial rather than on replication. **Magnitude:** Grade 1 or 2 anaemia affected 41 of 55 patients in the first-in-human study; anaemia was not a dose-limiting event on either the intermittent or the continuous schedule. #### Hepatic Transaminase Elevation Rises in aminotransferases (liver enzymes that leak into blood when liver cells are injured) were dose-limiting in the first-in-human study on both the intermittent and the continuous schedule ([Wilson et al., 2010](https://pubmed.ncbi.nlm.nih.gov/21094089/)). The events were reversible on interruption and no case of liver failure was reported. The grade reflects a single trial rather than replication across studies. **Magnitude:** Grade 3 aminotransferase elevation was a dose-limiting event in 1 of 38 patients on the intermittent schedule and 1 of 15 evaluable patients on the continuous schedule. ### Low 🟥 #### Clinically Significant Bleeding ⚠️ Conflicted Whether the platelet fall causes bleeding is disputed. Phase 1 recorded grade 3 gastrointestinal haemorrhage as a dose-limiting event ([Wilson et al., 2010](https://pubmed.ncbi.nlm.nih.gov/21094089/)); the platelet-floor-guided phase 2 trial reported 88% thrombocytopenia without clinically significant bleeding ([Harrison et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35180010/)). Net reading: bleeding is uncommon when dosing is platelet-guided. **Magnitude:** Grade 3 gastrointestinal bleeding occurred as a dose-limiting event in 1 of 15 evaluable patients on continuous dosing, against zero clinically significant bleeds among 34 platelet-monitored phase 2 patients. #### Cardiac Arrhythmia A grade 3 cardiac rhythm disturbance was recorded as a dose-limiting event on the intermittent schedule of the first-in-human study ([Wilson et al., 2010](https://pubmed.ncbi.nlm.nih.gov/21094089/)). It is a single uncontrolled observation in a heavily pretreated population, with no dose-response pattern and no replication in later trials. **Magnitude:** One grade 3 arrhythmia among 38 patients on the intermittent schedule; no later navitoclax trial has reported arrhythmia as a dose-limiting event. ### Speculative 🟨 #### Trabecular Bone Loss and Impaired Bone Formation Navitoclax in aged mice lowered senescent-cell burden yet cut trabecular (spongy inner) bone volume and impaired bone-forming marrow stromal cells ([Sharma et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32509782/)). The basis is rodent work; no human skeletal data exist. #### Accelerated Loss of Ovarian Reserve Two weeks of oral navitoclax in reproductively aged mice further depleted ovarian follicles (the egg reserve), implying a possible fertility cost ([Xia et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39369073/)). The basis is a small rodent study only. #### Worsening of Pulmonary Blood Pressure Through Loss of Lung Endothelial Cells Clearing senescent cells with navitoclax stripped out lung capillary lining cells and raised right-heart pressures in rodent models, rather than protecting them ([Born et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36515093/)). The basis is rodent work and human tissue markers. #### Destabilisation of Atherosclerotic Plaque Navitoclax thinned the fibrous cap that holds artery plaque together by 60% and was associated with over 50% mortality in mice with advanced atherosclerosis ([Karnewar et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38258907/)). The basis is rodent work only. #### Loss of Healthy Cells That Depend on BCL-xL Selectivity is partial, so any long-lived cell relying on BCL-xL is at risk. The concern is mechanistic, inferred from the platelet effect and the safety gain when BCL-xL is spared ([Khan et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31792461/)). ## Risk-Modifying Factors * **CYP3A5 expresser genotype:** No variant modifies navitoclax toxicity. CYP3A5 expressers clear CYP3A substrates faster, but CYP3A plays only a minor part in navitoclax elimination, so any effect on the platelet nadir (lowest point of the count) is small. * **Baseline platelet count:** The single strongest determinant of harm. Trials halve the starting dose at or below 150 × 10⁹/L and suspend dosing below 75 × 10⁹/L, because the drop is proportional to the starting count. * **CYP3A4 inducer exposure:** Rifampin lowered navitoclax exposure by about 41% without changing half-life ([Yang et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25047139/)). Chronic inducers therefore risk under-dosing rather than toxicity, while inhibitors add little exposure. * **Sex:** The mouse bone study found trabecular loss in both sexes, though larger in females (−60.1% versus −45.6%) ([Sharma et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32509782/)). No sex difference in human adverse events has been reported. * **Established osteoporosis or low bone density:** Given the rodent skeletal finding, pre-existing bone loss is the pre-existing condition of greatest theoretical concern, alongside liver impairment and any bleeding disorder. * **Concurrent anticoagulant or antiplatelet use:** Trial protocols excluded warfarin and platelet-function-altering drugs, permitting only low-dose aspirin up to 100 mg daily and low-molecular-weight heparin, because the combined bleeding risk is additive. * **Age and marrow reserve:** Older adults have lower marrow reserve and slower platelet recovery, so the same dose drives a deeper, longer nadir; this dominates age-related dosing at the older end of the range. ## Key Interactions & Contraindications * **Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St John's wort):** Caution. Navitoclax exposure fell about 41% with rifampin ([Yang et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25047139/)), risking loss of effect. Mitigation: separate courses, or select a non-inducing alternative rather than escalating dose blindly. * **Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice):** Monitor. Ketoconazole raised mean exposure only modestly, but two of ten patients saw five- to elevenfold rises ([Salem et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24692738/)), risking a deeper platelet nadir and severe thrombocytopenia. Mitigation: platelet monitoring if unavoidable. * **Anticoagulants (warfarin, apixaban, rivaroxaban) and antiplatelet drugs (clopidogrel, ticagrelor):** Absolute contraindication in trial protocols. Consequence: severe bleeding on top of drug-induced platelet loss. Mitigation: exclusion, with low-dose aspirin up to 100 mg daily the only permitted exception. * **Over-the-counter non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, high-dose aspirin):** Caution. These inhibit platelet function and irritate gastric mucosa, compounding bleeding risk. Mitigation: substitute paracetamol for routine analgesia during dosing periods. * **Marrow-suppressing chemotherapy (docetaxel, gemcitabine, irinotecan) and ruxolitinib:** Monitor closely. Overlapping marrow suppression produced grade 3 or 4 diarrhoea and fever with neutropenia in combination studies. Mitigation: reduced navitoclax dose, established at 150 mg daily with weekly irinotecan. * **Supplements with antiplatelet activity (fish oil, high-dose vitamin E, ginkgo, garlic extract, curcumin, nattokinase):** Caution. Additive bleeding risk against an already suppressed platelet count. Mitigation: pause these supplements before and throughout dosing periods. * **Senolytic supplements (quercetin, fisetin) and the prescription senolytic dasatinib:** Monitor. Combined senolytic pressure has not been tested in humans and may broaden off-target cell loss. Mitigation: avoid stacking senolytics within the same cycle. * **Grapefruit, pomelo and Seville orange:** Monitor. These inhibit intestinal CYP3A4 and may raise exposure unpredictably in the minority who are strongly affected, deepening the platelet fall. Mitigation: avoid during dosing days rather than adjusting dose. **Populations who should avoid Navitoclax:** * Baseline platelet count below 75 × 10⁹/L * Active bleeding, or a hereditary or acquired bleeding disorder * Requirement for therapeutic anticoagulation or dual antiplatelet therapy * Severe hepatic impairment (Child-Pugh Class C) * Recent major surgery (within 28 days) or planned surgery during dosing * Pregnancy and lactation * Established osteoporosis with a bone density T-score of −2.5 or below * Active uncontrolled infection, or absolute neutrophil count below 1.0 × 10⁹/L ## Risk Mitigation Strategies * **Platelet-guided lead-in dosing:** A seven-day lead-in at 150 mg daily before escalating to the target dose blunts the initial platelet nadir, the manoeuvre adopted after intermittent dosing produced dose-limiting thrombocytopenia in the first-in-human study ([Wilson et al., 2010](https://pubmed.ncbi.nlm.nih.gov/21094089/)). * **Hard platelet floor with dose interruption:** Trial protocols suspend dosing below 75 × 10⁹/L and resume at a reduced level once recovered, which is why phase 2 recorded no clinically significant bleeding despite 88% thrombocytopenia ([Harrison et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35180010/)). * **Weekly complete blood count during escalation:** A complete blood count — the standard panel of red cells, white cells and platelets — weekly through escalation and monthly thereafter detects the platelet, neutrophil and lymphocyte nadirs before they become symptomatic. * **Intermittent hit-and-run scheduling:** Senescent cells take weeks to reaccumulate, so short courses separated by drug-free intervals limit cumulative marrow and lymphocyte suppression relative to continuous daily dosing. * **Elimination of bleeding-risk co-medication:** Withdrawing anticoagulants, dual antiplatelet therapy, non-steroidal anti-inflammatory drugs and antiplatelet supplements before dosing removes the main route by which a low platelet count becomes a bleeding event. * **Liver enzyme monitoring at 2 and 4 weeks:** Aminotransferase rises were dose-limiting and reversible; checking alanine aminotransferase and aspartate aminotransferase early allows interruption before injury progresses. * **Infection precautions during lymphocyte nadir:** Because B- and T-cell recovery lags platelet recovery by months, vaccination before starting and prompt assessment of fever reduce the consequence of the immune deficit. * **Bone density assessment before extended use:** Given rodent trabecular bone loss, a baseline bone density scan identifies those in whom the skeletal signal would be least acceptable. ## Therapeutic Protocol * **Oncology monotherapy schedule:** The regimen taken furthest is a 150 mg daily oral lead-in for seven days, then 325 mg daily continuously in 21-day cycles, selected for phase 2 after dose-finding ([Wilson et al., 2010](https://pubmed.ncbi.nlm.nih.gov/21094089/)). * **Combination schedule with ruxolitinib:** In myelofibrosis, navitoclax is administered orally at 200 mg daily when platelets exceed 150 × 10⁹/L, or 100 mg daily escalated to 200 mg after seven days if platelets stay at or above 75 × 10⁹/L. * **Competing integrative approach:** The alternative senolytic approach in longevity practice uses generic agents — dasatinib with quercetin, or fisetin — given for three consecutive days at intervals, rather than any continuous BCL-xL-directed regimen. Neither approach has outcome trials in ageing. * **Preclinical senolytic schedule:** Rodent senolysis work uses roughly 50 mg/kg daily for five to fourteen days per cycle, with cycles repeated after weeks of washout; no human equivalent has been established for a senolytic indication. * **Expert attribution:** The senolytic framing originates with the Mayo Clinic group of Kirkland and Tchkonia and with Zhou's group; the myelofibrosis combination protocol was developed by AbbVie with investigators at Guy's and St Thomas' and MD Anderson. * **Best time of day:** Trials specify once-daily oral administration without a fixed clock time. Morning administration with food is conventional, allowing same-day recognition of gastrointestinal adverse events rather than overnight onset. * **Half-life and dose splitting:** The terminal half-life of roughly 15–25 hours supports once-daily administration. Trials used single daily doses throughout; no split-dose schedule has been evaluated, and splitting would not alter the platelet nadir. * **Genetic considerations:** No pharmacogenetic test guides navitoclax dosing. CYP3A4 and CYP3A5 variants are the plausible candidates given hepatic metabolism, but the modest effect of strong inhibitors suggests limited value in genotyping. * **Sex-based differences:** No sex-specific dose adjustment has been established. Human trials enrolled both sexes without stratified dosing, and the only sex-differentiated signal is the larger trabecular bone loss seen in female mice. * **Age-related considerations:** Older adults with reduced marrow reserve reach the platelet floor sooner. Protocols handle this by baseline-count-dependent starting doses rather than by chronological age, which applies equally at the older end of the range. * **Baseline biomarker dependence:** Starting dose is set by platelet count, and the likelihood of response tracks the BCL-2 family expression profile, with high MCL-1 predicting resistance and a high BIM-to-MCL-1 ratio predicting response. * **Pre-existing conditions:** Hepatic impairment, prior cytotoxic exposure and marrow fibrosis all reduce tolerated exposure, and protocols require adequate marrow, renal and hepatic function before the first dose. ## Discontinuation & Cycling * **Not intended as lifelong therapy:** Oncology use continues until benefit is lost or toxicity intervenes. The senolytic rationale is the opposite — short courses, because senescent cells take weeks to reaccumulate, making continuous exposure unnecessary. * **No withdrawal syndrome:** No rebound or withdrawal phenomenon has been described. Platelet counts recover within one to two weeks of stopping, reflecting the normal platelet lifespan rather than any adaptive change. * **Tapering not required:** Dose interruption rather than tapering is the protocol response to toxicity, and dosing resumes at a reduced level once counts recover. No taper schedule appears in any published navitoclax study. * **Cycling is the senolytic norm:** The hit-and-run logic makes intermittent cycling the expected schedule for senolytic use, since efficacy depends on clearing an accumulated burden rather than maintaining plasma levels. * **Slow lymphocyte recovery shapes the interval:** B-cell counts and immunoglobulin M remained suppressed for roughly a year in combination use ([Roberts et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25942994/)), so the drug-free interval is dictated by immune recovery, not by platelet recovery. ## Sourcing and Quality * **No approved commercial product:** Navitoclax has never received marketing approval in any jurisdiction. There is no licensed formulation, no manufacturer-issued prescribing information and no legitimate retail supply chain. * **Trial supply is the only validated route:** The film-coated tablet used in trials is supplied by AbbVie to registered investigational sites only. Material obtained outside that channel has no verified identity, purity or content. * **Research-chemical market risk:** Powders sold online as "ABT-263" are research reagents not manufactured to pharmaceutical standards. Reported purity certificates are supplier-generated and are not independent third-party testing. * **Compounding is not a workaround:** Compounding pharmacies cannot legally prepare an unapproved investigational agent, so the compounded-preparation route available for some off-label drugs does not exist here. * **Formulation matters for absorption:** Early capsule formulations were superseded by film-coated tablets after bioavailability studies, so a powder reconstituted informally would not reproduce trial exposure even at a nominally matched dose. ## Practical Considerations * **Time to effect:** The platelet fall begins within hours of the first dose. Spleen and symptom responses in trials were assessed at 24 weeks, while rodent senescent-cell clearance was measurable within days of a short course. * **Common pitfall — treating it as a supplement-grade senolytic:** Navitoclax is grouped in longevity writing with quercetin and fisetin, yet it carries a dose-limiting on-target toxicity those compounds do not, and requires laboratory monitoring. * **Common pitfall — ignoring the platelet floor:** Continuing through a falling platelet count is the error that produced dose-limiting bleeding in early studies, and platelet-guided interruption is what removed it in later ones. * **Regulatory status:** Investigational worldwide. Development for solid tumours was discontinued; the myelofibrosis programme reported phase 3 results. Any use outside a registered trial is unapproved and outside any regulatory safety framework. * **Cost and accessibility:** Effectively inaccessible outside trials. The competing senolytic agents are generic or over-the-counter, so institutional payers have a structural incentive to favour them, which also shapes which comparisons get funded. * **Monitoring burden:** Weekly blood counts during escalation and liver enzymes at 2 and 4 weeks mean the practical commitment is closer to that of cytotoxic therapy than to an oral longevity compound. ## Interaction with Foundational Habits * **Sleep:** No direct interaction is documented. Any indirect effect runs through adverse events — nocturnal diarrhoea or nausea can fragment sleep — so morning administration with food is preferred over evening administration to keep gastrointestinal symptoms in waking hours. * **Nutrition:** Direct interaction through intestinal CYP3A4. Trial protocols exclude grapefruit, pomelo and Seville orange on dosing days. Administration with food is conventional. Adequate protein and iron support marrow recovery; no nutrient depletion specific to navitoclax has been identified. * **Exercise:** Indirect and restrictive. A suppressed platelet count makes contact sport, heavy resistance work near failure and activities with fall risk hazardous during nadir. The rodent trabecular bone finding is a further argument for maintaining weight-bearing loading between cycles. * **Stress management:** No direct effect on cortisol or the stress response has been reported. The relevant interaction is indirect: infection risk during the lymphocyte nadir makes practices that preserve immune function, including sleep regularity, more consequential than usual during dosing periods. ## Monitoring Protocol & Defining Success Before a first dose, protocols require documentation of adequate marrow, kidney and liver function. That means a complete blood count with platelet count and differential, a comprehensive metabolic panel including alanine aminotransferase, aspartate aminotransferase and total bilirubin, serum creatinine with estimated glomerular filtration rate (eGFR, a calculated measure of kidney filtering capacity), and a coagulation screen. A baseline bone density scan is included in some protocols given the rodent skeletal signal, and baseline immunoglobulin levels give a reference point for the slow B-cell recovery that follows. Ongoing monitoring in trials ran weekly during dose escalation, then every two weeks to week 8, then monthly; liver enzymes were checked at weeks 2 and 4, and immunoglobulins every 3 months. Spleen and disease response were assessed at week 24 and every 12 weeks thereafter. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |---|---|---|---| | Platelet count | 200–400 × 10⁹/L; hold dosing below 75 × 10⁹/L | Dose-limiting on-target toxicity | Conventional reference 150–450 × 10⁹/L; nadir within days of dose change, recovery 1–2 weeks after stopping | | Absolute neutrophil count | 2.0–5.0 × 10⁹/L | Infection risk from progenitor loss | Conventional lower limit 1.5 × 10⁹/L; check with the same complete blood count draw | | Absolute lymphocyte count | 1.5–3.0 × 10⁹/L | B- and T-cell depletion from BCL-2 inhibition | Conventional reference 1.0–4.8 × 10⁹/L, so a conventionally normal count can still be below the functional floor; recovers over months, far slower than platelets; no fasting required | | Haemoglobin | 14.0–15.0 g/dL (men); 13.0–14.0 g/dL (women) | Detects anaemia, common in combination use | Conventional lower limits 13.5 and 12.0 g/dL; pair with ferritin if falling | | Alanine aminotransferase (ALT) | Below 25 U/L (men); below 20 U/L (women) | Dose-limiting liver enzyme rise | Alanine aminotransferase is a liver enzyme; conventional upper limit near 40 U/L; draw fasting with aspartate aminotransferase | | Aspartate aminotransferase (AST) | Below 25 U/L | Confirms hepatic origin when alanine aminotransferase rises | Conventional upper limit near 40 U/L; aspartate aminotransferase also rises with muscle injury, so interpret alongside creatine kinase after hard exercise | | Total bilirubin | 0.3–1.0 mg/dL | Detects impaired bile handling | Rises with fasting and with Gilbert's syndrome, a harmless inherited variant; draw with the liver panel | | Estimated glomerular filtration rate (eGFR) | Above 90 mL/min/1.73 m² | Protocol entry requirement and safety floor | Conventional threshold is 60 mL/min/1.73 m²; estimated glomerular filtration rate is calculated from creatinine; avoid heavy exercise and creatine supplements for 48 hours before | | Immunoglobulin M | 40–230 mg/dL | Tracks the sustained B-cell deficit | Fell roughly 33% over the first year in combination use ([Roberts et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25942994/)); check every 3 months | | Senescent-cell burden (p16INK4a expression) | No established target exists; track change from the individual's own baseline | Gauges whether senolysis actually occurred | p16INK4a is a gene switched on in senescent cells; measured on research assays only, not clinically validated | Qualitative markers tracked alongside laboratory values: * Easy bruising, gum bleeding, nosebleeds or petechiae (pinpoint red skin spots) — the earliest visible sign of a falling platelet count * Frequency, duration and severity of infections, particularly during the lymphocyte nadir * Stool frequency and consistency, since diarrhoea is the most common non-blood adverse event * Energy levels and exercise tolerance, which fall early when haemoglobin drops * Appetite and nausea, which drive discontinuation more often than laboratory abnormalities ## Emerging Research * **TRANSFORM-2 in relapsed myelofibrosis:** A randomised phase 3 trial of navitoclax plus ruxolitinib against best available therapy in 330 adults with relapsed or refractory disease, with spleen volume change as the primary endpoint ([NCT04468984](https://clinicaltrials.gov/study/NCT04468984)). * **REFINE long-term follow-up:** The 191-patient phase 2 platform that generated the fibrosis and survival signals has now completed, with registry results posted; extended follow-up will test whether fibrosis regression translates into survival ([NCT03222609](https://clinicaltrials.gov/study/NCT03222609)). * **Navitoclax with venetoclax and decitabine:** A phase 1 study in relapsed acute myeloid leukaemia previously treated with venetoclax, testing whether adding BCL-xL blockade overcomes resistance, at the cost of compounded platelet toxicity ([NCT05222984](https://clinicaltrials.gov/study/NCT05222984)). * **Targeted BCL-xL degraders as successors:** DT2216 converts navitoclax into a degrader that spares platelets, and is now in a phase 1b dose-escalation trial of 30 participants with platinum-resistant ovarian cancer, with maximum tolerated dose as the primary endpoint ([NCT06964009](https://clinicaltrials.gov/study/NCT06964009)); the preclinical rationale is set out by [Khan et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31792461/). * **Sugar-tagged navitoclax could rescue the compound:** Attaching a galactose tag releases navitoclax only inside senescent cells and cut platelet death in human and mouse blood ([González-Gualda et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32233024/)). Confirmation in a living organism would widen the safety margin substantially. * **Evidence that could weaken the case:** The finding that navitoclax causes trabecular bone loss in aged mice while still clearing senescent cells ([Sharma et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32509782/)) predicts that longer senolytic courses may trade one age-related outcome for another. * **Evidence that could strengthen the case:** Reports that navitoclax restores aged stem cell function ([Chang et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26657143/)) and improves survival after heart attack in aged mice ([Walaszczyk et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30920115/)) would, if reproduced in people, establish senolysis as a clinical strategy. * **The missing trial:** No registered study tests navitoclax against any ageing-related endpoint in humans. Among 43 registered navitoclax studies, every one is oncological, so the senolytic case rests entirely on animal work. ## Conclusion Navitoclax is an oral compound that blocks three of the proteins cells use to stay alive, and worn-out senescent cells depend heavily on two of them. That is a clean rationale, and in animals it delivers: senescent cells disappear, aged stem cells regain function, and hearts recover better after injury. In people, none of this has been measured. Every human result comes from cancer medicine, where the drug shrinks enlarged spleens and shrinks tumours — real effects, but effects on cancer rather than on the burden of worn-out cells. The obstacle is not subtle. Platelets rely on the same protein the drug was built to block, so the platelet count falls in proportion to the dose, in every study of it so far. Careful dose interruption keeps that from becoming bleeding, but it also caps how much drug can be given. Shortages of infection-fighting and antibody-making white cells follow, and recover slowly. A study in aged mice found bone thinning even as senescent cells were cleared. The evidence base is narrow and one-sided: the human trials were designed and funded by the manufacturer, and the longevity case rests on short rodent studies. Efforts to redesign the compound so that it spares platelets are where the field has moved, and they are early. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**